Grifols, S.A. (GRFS) vs GSK PLC Sponsored ADR (GSK)
- Grifols, S.A. GRFS 7.64 +1.33%
- GSK PLC Sponsored ADR GSK 49.55 +1.08%
Grifols, S.A. and GSK PLC Sponsored ADR are both Drug Manufacturers General companies. GSK PLC Sponsored ADR is the larger, with a market value of $98.2B against $2.0B — 50.4× the size. Grifols, S.A. trades at the lower P/E: 8.5× against 15.4×. Grifols, S.A. grew revenue faster over the last twelve months: 16.0% against 8.72%. GSK PLC Sponsored ADR has the higher net margin (14.6% vs 5.54%) and the higher return on invested capital (12.6% vs 0.00%). Both pay a dividend; GSK PLC Sponsored ADR yields more (3.67% vs 1.24%). Across the 23 metrics below, Grifols, S.A. leads on 12 and GSK PLC Sponsored ADR on 11.
Valuation
Profitability
| Metric | GRFS | GSK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 37.45% | 72.75% | 72.77% |
| Operating margin | 16.43% | 19.55% | 18.77% |
| Net margin | 5.54% | 14.58% | 8.27% |
| Free cash flow margin | 0.00% | 17.18% | 17.18% |
| Return on equity | 0.00% | 30.74% | 5.87% |
| Return on assets | 0.00% | 8.01% | 2.57% |
| Return on invested capital | 0.00% | 12.58% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack